Emergent

Emergent Overview

Company Headquarters: Maryland, US

Founded: 1998

Workforce: ~2,500

Company Working: Emergent is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). Its solutions include product portfolio, products that are under development (pipeline products), and contract development and manufacturing (“CDMO”). Revenues are generated by the sale and procurement of the company's product/product candidate portfolio, the provision of CDMO services to external customers, and non-dilutive contract and grant funding for research and development ("R&D") projects from various third-party sources

Strategy

Emergent invests in its current network of manufacturing facilities to enhance operational, quality, and compliance processes across the company in order to offer consistent delivery of products and services for both its own products and those of CDMO clients. It intends to focus on creating innovative solutions that meet unmet needs in the PHT area by expanding its pipeline of vaccines and therapeutic product candidates. It invests its own capital and secures government contracts, grants, or other non-dilutive funding to support pipeline expansion

Company Snapshot

2,500

Employees

1998

Founded

Maryland, US

Headquarters

SWOT Analysis

Strengths

Strong client base
Well established R&D facilities
Highly skilled workforce

Weaknesses

Declining company revenue
Delays in product approvals

Opportunities

Growing infectious diseases
Increasing technological advancements

Threats

Increasing competition in the market
Changes in government regulations

Key Developments

Date	Approach	Development
September 2022	–	Emergent BioSolutions Inc. announced the completion of its acquisition of exclusive worldwide rights to TEMBEXA (brincidofovir), the first oral antiviral licensed by the US Food and Drug Administration (FDA) for the treatment of smallpox in all age groups, from Chimerix.
March 2020	–	Emergent BioSolutions Inc. signed an agreement with Novavax Inc., (US) to Manufacture NanoFlu. Emergent will offer molecule-to-market contract development and manufacturing (CDMO) services to Novavax to produce NanoFlu, a recombinant quadrivalent seasonal influenza vaccine candidate including the company's proprietary Matrix-M adjuvant.
January 2020	–	Emergent BioSolutions Inc. announced that the European Medicines Agency (EMA) has agreed to proceed with its planned development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.

Product Offering

Emergent
- Biodefense Market

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.